Novel therapies for the treatment of inflammatory airway disease

Bibliography

• BARNES PJ: New treatments for COPD. Nat. Rev Drug Discov. (2002) 1:437–446.
   PubMed Web of Science ®Google Scholar
• ••An excellent recent review.
   Google Scholar
• JEFFERY PK: Comparison of the structuraland inflammatory features of COPD and asthma. Giles F. Filley Lecture. Chest (2000) 117:251S–260S.
   Google Scholar
• •A useful comparative study of C OPD and asthma.
   Google Scholar
• BARNES PJ: Mechanisms in COPD: differences from asthma. Chest (2000) 117:10S–14S.
   Google Scholar
• KERJSTENS HAM, GROEN HJ, VAN DER BIJ W: Recent advances in respiratory medicine. BM/(2001) 323:1349–1353.
   PubMed Web of Science ®Google Scholar
• PAHL A, SZELENYI I: Asthma therapy in the new millennium. Inflamm. Res. (2002) 51:273–282.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review.
   Google Scholar
• RUTTEN VAN-MOLKEN MP, FEENSTRA TL: The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics (2001) 19:1–6.
   PubMed Web of Science ®Google Scholar
• LOPEZ AD, MURRAY CC: The global burden of disease, 1990-2020. Nat. Med. (1998) 4:1241–1243.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: New treatments for chronic obstructive pulmonary disease. Curt: Opin. Pharmacol (2001) 1:217–222.
   PubMedGoogle Scholar
• PAUWELS RA, BUIST S, CALVERLEYPM, JENKINS CR, HURD SS: Global strategy for the diagnosis management and prevention of chronic obstructive Pulmonary disease. NHLBI/WHO Global initiative for chronic obstructive lung disease (GOLD) Workshop summary. Am. Respir. Crit. Care Med. (2001) 163:1256–1276.
   PubMedGoogle Scholar
• BARNES PJ: Chronic obstructive pulmonary disease. N Eng. I Merl (2000) 343:269–280.
   PubMed Web of Science ®Google Scholar
• SAETTA M, TURATO G, MAESTRELLI P, MAPP CE, FABBRI LM: cellular and structural basis of chronic obstructive pulmonary disease. Am. I Respir. Crit. Care Med. (2001) 163:1304–1309.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SD: End-stage chronic obstructive pulmonary disease: the cigarette is burned out but the inflammation rages on. Am. J. Respir. Crit. Care Med. (2001) 164:339–340.
   PubMed Web of Science ®Google Scholar
• NATIONAL INSTITUTES OF HEALTH. NATIONAL HEART LUNG AND BLOOD INSTITUTE: Global initiative for asthma. Global strategy for asthma management and prevention. NHLBI/WHO Workshop Report. Publication Number 02-3659 (2002):16.
   Google Scholar
• •Recently updated asthma management and prevention guidelines.
   Google Scholar
• DJUKANOVIC R: Asthma: a disease of inflammation and repair. I Allergy Clin. Immunol (2000) 105:S522–S526.
   PubMed Web of Science ®Google Scholar
• BJERMER L: History and future perspectives of treating asthma as a systemic and small airway disease. Respir. Med. (2001) 95:703–719.
   PubMed Web of Science ®Google Scholar
• BARNES PJ: The Pharmacological properties of Tiotropium. Chest (2000) 117:63S–66S.
   Google Scholar
• TAYLOR DA, JENSEN MW, KANABAR V et al.: A dose-dependent effect of the novel inhaled corticosteroid ciclesonide on airway responsiveness to adenosine-5-monophosphate in asthmatic patients. Am. Respir. Crit. Care Med. (1999) 160:237–243.
   PubMed Web of Science ®Google Scholar
• DENT G: Ciclesonide (Byk Gulden). Can: Opin. Investig. Drugs (2002) 3:78–83.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of cidesonide.
   Google Scholar
• CASABURI R, MAHLER DA, JONES PW et al: A long-term evaluation of once daily inhaled tiotropium in chronic obstructive pulmonary disease. Ear: Resp. (2002) 19:217–224.
   PubMed Web of Science ®Google Scholar
• VINCKEN W, VAN NOORD JA, GREEFHORST AP et al.: Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Ear: Resp. J. (2002) 19:209–216.
   Google Scholar
• VAN NOORD JA, BANTJETA, ELAND ME, KORDUCKI L, CORNELLISSEN PJ: A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax (2000) 55:289–294.
   Google Scholar
• DONOHUE JF, VAN NOORD JA, BATEMAN ED et al.: A 6-month, placebo controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest (2002) 122:47–55.
   PubMed Web of Science ®Google Scholar
• MAHLER DA, WIRE P, HORSTMAN D et al.: Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. Respir. Grit. Care Med. (2002) 166:1084–1091.
   PubMed Web of Science ®Google Scholar
• JORENBY D: Clinical efficacy of bupropion in the management of smoking cessation. Drugs (2002) 62:25–35.
   PubMed Web of Science ®Google Scholar
• GLICK SD, MAISONNEUVE IM, KITCHEN BA: Modulation of nicotine self administration in rats by combination therapy with agents blocking a334 nicotinic receptors. Ear: Pharmacol (2002) 448:185–191.
   PubMed Web of Science ®Google Scholar
• WILLIAMS TJ, JOSE PJ: Neutrophils in chronic obstructive pulmonary disease. Novartis Found. Symp. (2001) 234:136–141.
   PubMed Web of Science ®Google Scholar
• SILBAUGH SA, STENGEL PW, COCKERHAM SL et al.: Pharmacologic actions of the second generation leukotriene receptor antagonist LY293111: in vivo pulmonary studies. Naunyn-Schmiedebergs Arch. Pharmacol (2000) 361:397–404.
   PubMed Web of Science ®Google Scholar
• LEE E, LINDOT, JACKSON N et al.: Reversal of human neutrophil survival by leukotriene B(4) receptor blockade and 5-lipoxygenase and 5-lipoxygense activating protein inhibitors. Am. J. Respir. Grit. Care Med. (1999) 160:2079–2085.
   PubMed Web of Science ®Google Scholar
• GOMPERTZ S, STOCKLEY RA: A randomised, placebo-controlled trial of a leukotriene synthesis inhibitor in patients with COPD. Chest (2002) 122:289–294.
   PubMed Web of Science ®Google Scholar
• YANG XD, CORVALAN JR, WANG P, ROY CM, DAVIS CG: Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states. Leukoc. Biol. (1999) 66:401–410.
   PubMed Web of Science ®Google Scholar
• WOOLHOUSE IS, BAYLEY DL, STOCKLEY RA: Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax (2002) 57:709–714.
   PubMed Web of Science ®Google Scholar
• OWEN C: Chemokine receptors in airway disease: which receptors to target? Palm. Pharmacol Ther. (2001) 14:193–202.
   Web of Science ®Google Scholar
• HAY DW, SARAU HM: Interleuldn-8-receptor antagonists in pulmonary diseases. Carr: Opin. Pharmacol (2001) 1:242–247.
   Google Scholar
• WHITE JR, LEE JM, YOUNG PR et at.:Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. Biol. Chem. (1998) 273:10095–10098.
   Google Scholar
• AUTEN RL, RICHARDSON RIVI, WHITE JR, MASON SN, VOZZELLI MA, WHORTON MH: Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats.' Pharmacol Exp. Ther (2001) 299:90–95.
   PubMed Web of Science ®Google Scholar
• DE BOER WI, SONT JK, VAN SCHADEWIJK A, STOLK J, VAN KRIEKEN JH, HIEMSTRA PS: Monocyte chemoattractant protein 1, interleukin 8 and chronic airways inflammation in COPD.J Pathol (2000) 190:619–626.
   PubMed Web of Science ®Google Scholar
• MAUS U, VON GROTE K, KUZIEL WA: The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am. I Respir. Grit. Care Med (2002) 166:268–273.
   PubMed Web of Science ®Google Scholar
• BOCCHINO V, BERTORELLI G, BERTRAND CP et al.: Eotaxin and CCR3 are up-regulated in exacerbations of chronic bronchitis. Allergy (2002) 57:17–22.
   PubMed Web of Science ®Google Scholar
• KEATINGS VM, COLLINS PD, SCOTT DM, BARNES PJ: Differences in interleukin-8 and tumour necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. I Respir. Crit. Care Med. (1996) 153:530–534.
   PubMed Web of Science ®Google Scholar
• BLACK RA: Tumour necrosis factor-alphaconverting enzyme. Int. Biochem. Cell Biol. (2002) 34:1–5.
   PubMed Web of Science ®Google Scholar
• TRIFILIEFF A, WALKER C, KELLER T, KOTTIRSCH G, NEUMANN U: Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br. Pharmacol (2002) 135:1655–1664.
   PubMed Web of Science ®Google Scholar
• GIEMBYCZ MA: Development status ofsecond generation PDE4 inhibitors for asthma and COPD: the story so far. Monaldi Arch. Chest D AK (2002) 57:48–64.
   PubMedGoogle Scholar
• GIEMBYCZ MA: Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin. Investig. Drugs (2001) 10:1361–1379.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of cilomilast.
   Google Scholar
• REID P: Roflumilast Altana Pharma. Carr.Opin. Investig. Drugs (2002) 3:1165–1170.
   PubMedGoogle Scholar
• STURTON G, FITZGERALD M: Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest (2002) 121:192S–196S.
   Google Scholar
• COMPTON CH, GUBB J, NIEMAN R: Cilomilast, a selective phosphodiesterase-4 inhibitor for the treatment of patients with chronic obstructive pulmonary disease: a randomised, dose ranging study. Lancet (2001) 358:265–270.
   PubMed Web of Science ®Google Scholar
• GAMBLE E, PAVORD ID, VIGNOLA AM: Cilomilast (Ariflo9, a novel treatment for COPD, reduces the key inflammatory cells in bronchial biopsies. AmRespir.Grit. Care Med. (2002) 165:A227.
   Google Scholar
• KELSEN SG, YANG Y, BIN W, LI X, AKSOY MO: Cilomilast and salmeterol inhibit chemokine release by human airway epithelial cells. Am . Respir. Grit. Care Med. (2002) 165:A194.
   Google Scholar
• LEICHTL S, SYED J, BREDENBROKER D, RATHGEB, WURST W: Efficacy of once-daily Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in chronic obstructive pulmonary disease. Am. Respir. Grit. Care Med. (2002) 165:A229.
   PubMedGoogle Scholar
• LAMONTAGNE S, MEADOWS E, LUK P: Localisation of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey. Brain Res (2001) 920:84–96.
   PubMed Web of Science ®Google Scholar
• TRIFILIEFF A, WYSS D, WALKER C, MAZZONI L, HERSPERGER R: Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo [1,2,5] oxadiazol- 5 -yl-[1,71napthyridin-6-y1)-benzoic acid (NVP-ABE171), a 1,7-nathyridine derivative, with anti-inflammatory activities. Pharmacol Exp. Ther. (2002) 301:241–248.
   PubMed Web of Science ®Google Scholar
• HADDAD EB, BIRRELL M, MCCLUSKIE K et al: Role of p38 MAP kinase in LPS-induced airway inflammation in the rat. Br. PharmacoL (2001) 132:1715–1724.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S et al: SB 239063, a P38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. j Physiol Lung Cell Mol Physiol (2000) 279:L895–L902.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SD: Proteinases in chronic obstructive pulmonary disease. Biochem. Soc. Trans. (2002) 30:98–102.
   PubMed Web of Science ®Google Scholar
• NADEL J: Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest (2000) 117:386S–389S.
   Google Scholar
• FITZGERALD ME SPICER D, FOX C, KOBAYASHI DK, SHAPIRO S: Effect of acute and chronic exposures to cigarette smoke in two strains of mice. Efficacy of a matrix metalloproteinases (MMP) inhibitor, BAY 15–7496, on emphysema development. Am . Respir Crit. Care Med. (2002) 165:A824.
   Google Scholar
• CHURG A, ZAY K, SHAY S: Acute cigarette smoke induced connective tissue breakdown requires both neutrophils and macrophage metalloelastase in mice. Respir. Cell. Ma Biol. (2002) 278:368–374.
   Google Scholar
• RUSSEL RE, CULPITT SV, DEMATOS C et al.: Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Ma Biol. (2002) 26:602–609.
   Google Scholar
• WRIGHT JL, FARMER SG, CHURG A: Synthetic serine elastase inhibitor reduces cigarette smoke-induced emphysema in guinea pigs. Arn Respir. Grit. Care Med. (2002) 166:954–960.
   PubMed Web of Science ®Google Scholar
• STOCKLEY RA, BAYLEY DL, UNSAL I, DOWSON LJ: The effect of augmentation therapy on bronchial inflammation in a- 1-antitrypsin deficiency. Jim. j Respir. Grit. Care Med (2002) 165:1494–1498.
   PubMed Web of Science ®Google Scholar
• OHBAYASHI H: Neutrophil elastase inhibitors as treatment for COPD. Expert Opin. Investig. Drugs (2002) 11:965–980.
   PubMed Web of Science ®Google Scholar
• KURAKI T, ISHIBASHI M, TAKAYAMA M, SHIRAISHI M, YOSHIDA M: A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. Jim. I Respir. Crit. Care Med (2002) 166:496–500.
   PubMed Web of Science ®Google Scholar
• LEUNG-TOUNG R, LI W, TAM TF, KARIMIAN K: Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem. (2002) 9:979–1002.
   PubMed Web of Science ®Google Scholar
• MASSARO G, MASSARO D: Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat. Med. (1997) 3:675–677.
   PubMed Web of Science ®Google Scholar
• •First observation of the beneficial effects of retinoic acid on alveolar regrowth.
   Google Scholar
• HIND M, MADEM M: A mouse model of alveolar regeneration. Am .1 Respir. Grit. Care Med (2002) 165:A223.
   Google Scholar
• FRANKENBERGER M, HAUCK RW, FRANKENBERGER B: All trans retinoic acid selectively down-regulates matrix metalloproteinase-9 (MMP-9) and up-regulates tissue inhibitor of metalloproteinase-1 TIMP-1) in human bronchoalveolar lavage cells. Mol. Med (2001) 7:263–270.
   PubMed Web of Science ®Google Scholar
• OFULUE A: Retinoids reverse cigarette smoke-induced emphysema in rats. Am. J. Respir. Crit. Care Med. (2002) 165:B7.
   Google Scholar
• MAO C, BAILEY-HEALEY I, GATER PR, BELLONI P: Effects of R0444753, a synthetic retinoid agonist, on morphologic and lung function changes in a rat model of emphysema. Am . I Respir. Crit. Care Med (2002) 165:A825.
   Google Scholar
• TODD G, DUNLOP K, MCNABOE J, RYAN ME CARSON D, SHIELDS MD: Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet (1996) 348:27–29.
   PubMed Web of Science ®Google Scholar
• WHOL E, MAJZOOB J: Asthma, steroidsand growth. N Engl. I Med. (2000) 343:1113–1114.
   PubMed Web of Science ®Google Scholar
• O'CONNOR BJ, SIPS P, ENGELSTATTER R, STEINIJANS VW, WURST W: Management of moderate to severe bronchial asthma by Ciclesonide: a 12 week trial. Am. I Respir. Grit. Care Med. (2002) 165:A767.
   Google Scholar
• CHAPMAN KR, D'URZO AD, OEDEKOVEN C, STEINIJANS VW, WURST W: Effects of Ciclesonide versus placebo on lung function after 12 weeks of treatment in patients with asthma. Am. I Respir. Crit. Care Med. (2002) 165:A767.
   Google Scholar
• ENGELSTATTER R, LANGDON C, BETHKE T, RATHGEB F, STEINIJANS VW, WURST W: Inhaled corticosteroids: efficacy and adverse effects. Am . Respir. Grit. Care Med. (2002) 165:A766.
   PubMedGoogle Scholar
• WEINBRENNER A, HUNEKE D, ZSCHIESCHE M et al: Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. Clin. Endocrinol Metab. (2002) 87:2160–2163.
   Google Scholar
• PAUWELS RA, DEROM E, VAN DE VELDE V, MARISSENS S, VINCKEN W: Effects of inhaled Ciclesonide and fluticasone propionate on cortisol secretion and PC20 for adenosine in asthma patients. Am. I Respir. Crit. Care Med (2002) 165:A768.
   Google Scholar
• FOZARD JR, MANLEY PW: Potassiumchannel openers: agents for the treatment of airway hyperreactivity. In: New drugs for asthma, allergy and COPD (Vol. 31). TT Hansel, PJ Barnes (Eds), Karger, Basel, Switzerland (2001):77–80.
   Google Scholar
• BUCHHEIT KH, MANLEY PW, QUAST U, RUSS U, MAZZONI L, FOZARD JR: KC0912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of cardiovascular effects. Naunyn-Schnnederbergs Arch. Pharmacol (2002) 365:220–230.
   PubMed Web of Science ®Google Scholar
• LARCHE M, TILL SJ, HASELDEN BM et al.: Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics. Immunol (1998) 161:6375–6382.
   Web of Science ®Google Scholar
• VAN OOSTERHOUT AJ, HOFSTRA CL, SHIELDS R: Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE upregulation in murine model of allergic asthma. Am..! Respir. Cell Mol Biol. (1997) 17:386–392.
   PubMed Web of Science ®Google Scholar
• DEURLOO DT, VAN ESCH BC, HOFSTRA CL, NIJKAMP FP, VAN OOSTERHOUT AJ: CTLA4-IgG reverses asthma manifestations in a mild but not in a more "severe" ongoing murine model. Am. Respir. Cell Ma Biol. (2001) 25:751–760.
   PubMed Web of Science ®Google Scholar
• NORMAN PS: Immunotherapy: past andpresent. (1998) 1 Allergy Clin. Immunol 102:1–10.
   Google Scholar
• HANSEL TT, BARNES PJ: Novel drugs for treating asthma. Curr. Allergy Asthma Rep. (2001) 1:164–173.
   PubMedGoogle Scholar
• LARCHE M: Anti-T-cell strategies in the treatment of allergic disease. Allergy (2002) 57:20–23.
   PubMed Web of Science ®Google Scholar
• FICK RB: Anti-IgE as novel therapy for the treatment of asthma. Curt: Opin. Pulm. Med. (1999) 5:76–80.
   PubMedGoogle Scholar
• TUMAS DB, CHAN B, WERTHER W et al.: Anti-IgE efficacy in murine asthma models is dependent on the method of allergen sensitisation. Allergy Clin. Immunol (2001) 107:1025–1033.
   Google Scholar
• BERGER WE: Monoclonal anti-IgE antibody: a novel therapy for allergic airways disease. Ann. Allergy Asthma Immunol (2002) 8:152–160.
   Google Scholar
• HOLGATE S, BOUSQUET J, WENZEL S, FOX H, LIU J: Omalizumab improves disease control in patients at high risk of serious asthma-related morbidity and mortality. Am .I Respic Crit. Care Med (2002) 165:A187.
   Google Scholar
• BOUSQUET J, HOLGATE S, WENZEL S, FOX H, LIU J: Omalizumab reduces the incidence and frequency of exacerbations in patients at high risk of serious asthma-related morbidity and mortality. Am . Respir. Grit. Care Med. (2002) 165:A187.
   Google Scholar
• WENZEL S, BOUSQUET J, HOLGATE S, FREEMAN P, FOX H: Patients with more severe allergic asthma gain greatest relative benefit from omalizumab therapy. Am. I Respir: Crit. Care Med (2002) 165:A215.
   Google Scholar
• MCMILLAN RM: Leukotrienes in respiratory disease. Paediatr. Respir: Rev (2001) 2:238–244.
   PubMedGoogle Scholar
• DUCHARME FM: Anti-leukotrienes as add-on therapy to inhaled glucocorticoids in patients with asthma: systematic review of current evidence. BMJ(2002) 324:1545–1552.
   PubMed Web of Science ®Google Scholar
• BORISH L: The role of leukotrienes in upper and lower airway inflammation and the implications for treatment. Ann. Allergy Asthma Immunol (2002) 88:16–22.
   PubMed Web of Science ®Google Scholar
• CRETICOS P, KNOBIL K, EDWARDS LD, RICKARD KA, DORINSKY P: Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann. Allergy Asthma Immunol (2002) 88:401–409.
   PubMed Web of Science ®Google Scholar
• BUSSE W, NELSON H, WOLFE J, KALBERG C, YANCEY SW, RICKARD KA: Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. Allergy Clio. Immunol (1999) 103:1075–1080.
   PubMed Web of Science ®Google Scholar
• HART PH: Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol (2001) 79:149–153.
   PubMed Web of Science ®Google Scholar
• AKERS IA, PARSONS M, HILL MR et al: Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. j Physiol Lung Cell Ma Physiol (2000) 278:L193–L201.
   PubMed Web of Science ®Google Scholar
• SYLVIN H, DAHLBACK M, VAN DER PLOEG I, ALVING K. The tryptase inhibitor APC-366 reduces the acute airway response to allergen in pigs sensitised to Ascaris suum. Clio. Exp. Allergy (2002) 32:967–971.
   Google Scholar
• WRIGHT CD, HAVILL AM, MIDDLETON SC et al.: Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis- [4-[3- cabamimidoyl-benzenesulfonylamino)-methyl]-phenoxy-pentane (AMG-126737). Biochem. Pharmacol (1999) 58:1989–1996.
   PubMed Web of Science ®Google Scholar
• OH SW, PAE CI, LEE DK et al.: Tryptaseinhibition blocks airway inflammation in a mouse asthma model." Immunol (2002) 168:1992–2000.
   Google Scholar
• KRISHNA MT, CHAUHAN A, LITTLE L et al.: Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma. I Allergy Clio. Immunol (2001) 107:1039–1045.
   PubMed Web of Science ®Google Scholar
• LECKIE MJ, TEN BRINKE A, KHAN J et al.: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2001) 356:2144–2148.
   Web of Science ®Google Scholar
• KIPS JC, TOURNOY KG, PAUWELS RA: New asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5. Euc Respir: J. (2001) 17:499–506.
   PubMed Web of Science ®Google Scholar
• SUN Q, JONES K, MCCLURE B et al: Simultaneous antagonism of IL-5, granulocyte-macrophage colony stimulating factor, and IL-3 stimulation of human eosinophils by targeting the common cytokine binding site of their receptors. Blood(1999) 94: 1943-1951.
   Google Scholar
• RAMSHAW HS, WOODCOCK JM, BAGLEY CJ, MCCLURE BJ, HERCUS TR, LOPEZ AF: New approaches in the treatment of asthma. Immunol Cell Biol. (2001) 79:154–159.
   PubMed Web of Science ®Google Scholar
• BORISH LC, NELSON HS, CORREN J et al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. Allergy Clio. Immunol (2001) 107:963–970.
   PubMed Web of Science ®Google Scholar
• TOMKINSON A, DUEZ C, CIESLEWICZ G et al.: A murine IL-4 receptor antagonist that inhibits IL-4 and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. Immunol (2001) 166:5792–5800.
   Web of Science ®Google Scholar
• FOSTER PS, MARTINEZ-MOCZYGEMBA M, HUSTON DP, CORRY DB: Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease. Pharmacol Thec (2002) 94:253–264.
   PubMed Web of Science ®Google Scholar
• MULLINGS RE, WILSON SJ, PUDDICOMBE SM et al.: Signal transducer and activator of transcription 6 (STAT-6) expression and function in asthmatic bronchial epithelium.]: Allergy Clio. Immunol (2001) 108:832–838.
   Google Scholar
• TAYLOR PC: Anti-tumour necrosis factor therapies. Curc Opin. Rheumatol (2001) 13:164–169.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-BOTRAN R, CRESPO FA, SUN X: Soluble cytokine receptors in biological therapy. Expert Opin. Biol. Thec (2002) 2:585–605.
   PubMed Web of Science ®Google Scholar
• WEISMAN MH: What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.' Rheumatol Sapp]. (2002) 65:33–38.
   PubMedGoogle Scholar
• BARNES PJ: Cytokine modulators as novel therapies for asthma. Ann. Rev Pharmacol Toxicol (2002) 42:81–98.
   PubMed Web of Science ®Google Scholar
• HANSEN G, BERRY G, DEKRUYFF RH, UMETSU DT: Allergen-specific Thl cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation. I Clio. Invest. (1999) 103:175–183.
   PubMed Web of Science ®Google Scholar
• BRYAN SA, O'CONNOR BJ, MATTI S et al.: Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet (2000) 356:2149–2153.
   Google Scholar
• PRETOLANI M, GOLDMAN M: IL-10: a potential therapy for allergic inflammation? Immunol Today (1997) 18:277–280.
   PubMedGoogle Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology (2000) 119:1473–1482.
   PubMed Web of Science ®Google Scholar
• PROUDFOOT AE: Chemokine receptors: multifaceted therapeutic targets. Nat. Rev Immunol (2002) 2:106–115.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review of chemokinereceptors as therapeutic targets.
   Google Scholar
• BERTRAND CP, PONATH PD: CCR3 blockade as a new therapy for asthma. Expert Opin. Invest. Drugs (2000) 9:43–52.
   PubMed Web of Science ®Google Scholar
• WHITE JR, LEE JM, DEDE K et al.: Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration. I Biol. Chem. (2000) 275:626–631.
   Google Scholar
• SABROE I, PECK MJ, VAN KEULEN BJ et al.: A small molecule antagonist of chemokine receptors CCR1 and CCR3. Potent inhibition of eosinophil function and CCR3-mediated HIV-1 entry. I Biol. Chem. (2000) 275:985–992.
   Google Scholar
• WACKER DA, SANTELLA III JB, GARDNER DS et al.: CCR3 antagonists: A potential new therapy for the treatment of asthma. Discovery and structure-activity relationship. Bioorg. Med. Chem. Lett. (2002) 12:1785–1789.
   PubMed Web of Science ®Google Scholar
• D'AMBROSIO D, MARIANI M, PANINA-BORDIGNON P, SINIGAGLIA F: Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation. Am. I Respir. Grit. Care Med (2001) 164:1266–1275.
   PubMed Web of Science ®Google Scholar
• GATER P, SATJAWATCHARAPHONG C, STALEY C, SZCZEPANSKI K, KERTESZ D, BERTRAND CP: Effect of orally active CCR3 antagonists in animal models of allergic airway inflammation. Am. Respir. Crit. Care Med (2002) 165:A313.
   Google Scholar
• CAMPBELL EM, CHARO IF, KUNKEL SL et al.: Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells.' brimunol. (1999) 163:2160–2167.
   Google Scholar
• LLOYD CM, DELANEY T, NGUYEN T et al.: CC chemokine receptor (CCR)3/ eotaxin is followed by CCR4/monocyte-derived chemokine in mediating pulmonary T helper lymphocyte type 2 recruitment after serial antigen challenge in vivo.' Exp. Med. (2000) 191:265–274.
   Google Scholar
• TIMMER W, LECLERC V, BIRRAUX G et al.: The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNFa ex vivo.' Clin. Pharmacol (2002) 42:297–303.
   Google Scholar
• LEICHTL S, SCHMID-WIRLITSCH C, BREDENBROKER D, RATHGEB F, WURST W: Dose-related efficacy of once-daily Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, in asthma. Am. j Respir. Grit. Care Med (2002) 165:A185.
   PubMed Web of Science ®Google Scholar
• CARTER AB, MONICK MM, HUNNINGHAKE GW: Both erk and p38 kinases are necessary for cytokine gene transcription. Am. j Respir. Cell Ma Biol. (1999) 20:751–758.
   PubMed Web of Science ®Google Scholar
• LEE JC, KUMAR S, GRISWOLD DE et al.: Inhibition of p38 MAP kinase as a therapeutic strategy Immunopharmacology (2000) 47:185–201.
   Google Scholar
• BIRRELL M, HELE D, MCCLUSKIE K et al.: Effect of p38 kinase inhibitor, SB 203580, on sephadex induced airway inflammation in the rat. Eur. Respir. (2000) 16:947–950.
   PubMed Web of Science ®Google Scholar
• UNDERWOOD DC, OSBORN RR, KOTZER CJ et al.: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. Pharmacol Exp. Ther (2000) 293:281–288.
   PubMed Web of Science ®Google Scholar
• IRUSEN E, MATTHEWS JG, TAKAHASHI A, BARNES PJ, CHUNG KF, ADCOCK IM: p38 mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. Allergy Clin. brimunol. (2002) 109:649–657.
   PubMed Web of Science ®Google Scholar
• FOZARD JR, HANNON JP: Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. Pulm. Pharmacol The]: (1999) 12:111–114.
   PubMed Web of Science ®Google Scholar
• HOLGATE ST: Adenosine: a key effector molecule of asthma or just another mediator? Am. I Physiol Lung Cell Ma Physiol 282:L167–L168.
   Google Scholar
• FOZARD JR, MCCARTHY C: Adenosine receptor ligands as potential therapeutics in asthma. Carr. Opin. Investig. Drugs (2002) 3:69–77.
   PubMedGoogle Scholar
• •Informative review of adenosine receptors and ligands.
   Google Scholar
• SANDRASAGRA A, LEONARD SA, TANG L et al: Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. (2002) 12:177–181.
   PubMedGoogle Scholar
• FOZARD JR, ELLIS KM, VILLELA DANTAS MF, TIGANI B, MAZZONI L: Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur. Pharmacol (2002) 438:183–188.
   PubMed Web of Science ®Google Scholar
• GLAXOSMITHKLINE PLC: Product development pipeline February 2001. Company brochure (22 February, 2001).
   Google Scholar
• EZEAMUZIE CI: Involvement of A(3) receptors in the potentiation by adenosine of the inhibitory effect of theophylline on human eosinophil degranulation: possible novel mechanism of the anti-inflammatory action of theophylline. Biochem. Pharmacol (2001) 61:1551–1559.
   PubMed Web of Science ®Google Scholar
• SERHAN CN, DEVCHAND PR: Novel anti-inflammatory targets for asthma. A role for PPARy? Am. I Respir. Cell Ma Biol. (2001) 24:658–661.
   PubMed Web of Science ®Google Scholar
• WANG AC, DAI X, LUU B, CONRAD DJ: Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am. Respir. Cell Ma Biol. (2001) 24:688–693.
   PubMed Web of Science ®Google Scholar
• BENAYOUN L, LETUVE S, DRUILHE A et al.: Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am. I Respir. Crit. Care Med. (2001) 164:1487–1494.
   PubMed Web of Science ®Google Scholar
• OATES JC, REILLY CM, CROSBY MB, GS GILKESON: Perwdsome proliferator-activated receptor y agonists: potential use for treating chronic inflammatory diseases. Arthritis Rheum. (2002) 46:598–605.
   PubMed Web of Science ®Google Scholar
• BONNANS C, VACHIER I, CHAVIS C, GODARD P, BOUSQUET J, CHANEZ: Lipoxins are potential endogenous anti-inflammatory mediators in asthma. Am. J. Respir. Grit. Care Med. (2002) 165:1531–1535.
   PubMed Web of Science ®Google Scholar
• LEVY BD, DE SANCTIS GT, DEVCHAND PR et al.: Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nat. Med. (2002) 8:1018–1023.
   PubMed Web of Science ®Google Scholar
• KLINE JN: DNA therapy for asthma. Curr. Opin. Allergy Clin. Immunol (2002) 2:69–73.
   PubMedGoogle Scholar
• BELVISI MG: Overview of the innervation of the lung. Curr. Opin. Pharmacol (2002) 2:211–215.
   Google Scholar
• CHUNG KF: Cough: potential pharmacological developments. Expert Opin. Investig. Drugs. (2002) 11:955–963.
   PubMed Web of Science ®Google Scholar
• SPINA D, PAGE CP: Pharmacology of airway irritability. Carr. Opin. Pharmacol. (2002) 2:264–272.
   PubMed Web of Science ®Google Scholar
• BIRRELL MA, CRISPINO N, HELE DJ et al.: Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets. Br. Pharmacol (2002) 136:620–628.
   PubMed Web of Science ®Google Scholar